PF-Atlas › Clinical Trials › NCT02449031

Observational Study in Cystic Fibrosis Patients Using TOBI® PODHALER® or Other FDA Approved Inhaled Antipseudomonal Antibacterial Drugs

TOBI® PODHALER® · Not specified

Registry ID
NCT02449031
Phase
Not specified
Status
Completed
Drug / intervention
TOBI® PODHALER®
Sponsor
Mylan Inc.
Start
2015-05-05
Enrollment
409
Locations
47

About this trial

This is a multicenter, prospective, two cohort, observational study over a 5-year period in Cystic Fibrosis (CF) patients with chronic Pseudomonas aeruginosa infection.The study will collect data over 1 year on respiratory function, antibacterial effectiveness, and clinical outcomes of treatment with inhaled antipseudomonal antibiotics and data over 5 years on microbiological and safety assessments.

View NCT02449031 on ClinicalTrials.gov →

Explore related

All TOBI® PODHALER® trialsAll IPF trials
Medical disclaimer. This page summarizes public trial data for NCT02449031 for information only. It is not medical advice, an endorsement, or an offer to enroll. Confirm details on ClinicalTrials.gov and with a qualified physician.